Rani Therapeutics Holdings, Inc.

NASDAQ:RANI

Biotechnology

Healthcare
$0.80 -5.22%

-$0.04 today

Market cap
$52.19M
Beta
0.76
P/E (TTM)
-4.6
EPS (TTM)
-$0.16
52W Low $0.39High $3.87

Volume 0.23M

Average 1.15M

RANI EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Rani Therapeutics Holdings, Inc.NASDAQ: RANI

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$7.77M, compared with -$11.54M a year earlier. Trailing-twelve-month EBITDA was -$33.38M.

Context

  • EBITDA amounted to 2275.5% of revenue in FY2025, down 2639.2 pp from a year earlier.
  • EBITDA grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 3 analysts of -$5.59M (+84.9%) for the fiscal year ending Dec 2026, a step up from the +26.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$7.77M+9.1% QoQ
Last fiscal yearDec 2025
-$37.16M+26.5% YoY
LTMMar 2026
-$33.38M+31.6% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+32.7%+9.0%-23.7 pp
1 year+26.5%+84.9%+58.5 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(37.16M) USD
Year-over-year change
+26.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How RANI compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +31.6% is the highest of 9, against a peer median of -10.4%.
  • EBITDA amounts to 1053.3% of revenue for RANI, versus a peer median of 1566.1%.
RANI Competitors
EBITDA for RANI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026-$33.38M USD+31.6%—1053.3%
ELTXElicio Therapeutics, Inc.LTM Mar 2026-$37.68M USD+23.9%——
IPHAInnate Pharma S.A.FY2025-€43.65M EUR+7.0%—1566.1%
CRDFCardiff Oncology, Inc.LTM Mar 2026-$43.73M USD+9.5%—8329.5%
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026-$61.36M USD-27.4%—3439.7%
MOLNMolecular Partners AGLTM Mar 2026-CHF 63.08M CHF-8.3%——
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026-$84.28M USD-67.4%——
SGMOSangamo Therapeutics, Inc.LTM Mar 2026-$117.46M USD-66.2%—339.9%
TNXPTonix Pharmaceuticals Holding Corp.LTM Mar 2026-$145.4M USD-12.5%—828.2%
Peer median (excluding RANI) —-10.4%—1566.1%

Competitors are the stored peer set for RANI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.72M001.03M1.63M
Cost of Revenue00822K0900K
Gross Profit2.72M0(822K)1.03M733K
Gross Margin100.0%——100.0%44.9%
Research & Development26.48M36.61M39.62M26.68M20.21M
Selling, General & Admin27.83M26.84M26.48M23.95M19.74M
Operating Expenses54.32M63.45M65.28M54.34M39.04M
Depreciation & Amortization497K548K822K1.03M900K
EBITDA(52.08M)(61.66M)(61.98M)(50.52M)(37.16M)
EBITDA Margin-1917.0%——-4914.7%-2275.5%
Operating Income(51.6M)(63.45M)(66.1M)(53.31M)(38.31M)
Operating Margin-1899.1%——-5186.2%-2346.0%
Interest Income89K1.25M3.3M1.76M827K
Interest Expense466K1.07M5.09M5.03M2.89M
Other Income / Expenses(1.45M)177K(1.78M)23.3M(2.64M)
Income Before Tax(53.05M)(63.27M)(67.88M)(30.02M)(40.95M)
Pre-Tax Margin-1952.4%——-2920.0%-2507.7%
Income Tax Expense41K70K026.57M0
Net Income(8.33M)(30.59M)(33.97M)(30.02M)(29.67M)
Net Margin-306.6%——-2920.0%-1817.1%
EPS (Basic)(0.42)(1.28)(1.33)(1.05)(0.45)
EPS (Diluted)(0.42)(1.28)(1.33)(1.05)(0.45)
Weighted Avg Shares19.53M23.82M25.51M28.48M66.14M
Weighted Avg Shares (Diluted)19.53M23.82M25.51M28.48M66.14M

Rani Therapeutics Holdings, Inc.

NASDAQ:RANI

Intrinsic Alpha fair value

Locked

Current Price

$0.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.